title: Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087.
abstract: OBJECTIVE
  Statins and fibrates alter lipids, apolipoproteins and inflammatory markers in persons without HIV. The objective of this study was to evaluate changes in lipoproteins, apolipoproteins and other markers of inflammation with the use of pravastatin and fenofibrate.
  
  
  METHODS
  Evaluation of participants in ACTG A5087, a randomized trial of pravastatin 40 mg/day or fenofibrate 200 mg/day for the treatment of dyslipidemia. Participants that failed single-agent therapy at week 12 were given the combination.
  
  
  METHODS
  Participants with available specimens were tested for apolipoproteins A1 and B, adiponectin, plasminogen-activator inhibitor type 1 (PAI-1), P-selectin, and high-sensitivity C-reactive protein (hs-CRP).
  
  
  RESULTS
  74 participants (37 per randomized arm) received either pravastatin or fenofibrate for 12 weeks with 60 receiving combination treatment from weeks 12-48. There were no significant changes in hs-CRP, PAI-1, and P-selectin. From baseline to week 12, the median Apo B levels (-8 mg/dL, P=0.01 for fenofibrate and -27 mg/dL, P<0.01 for pravastatin) and ApoB/A1 ratios (-0.16, P<0.01 for both arms) significantly decreased. From baseline to week 48, median adiponectin (-1 ng/dL, P<0.01), Apo B (-22 mg/dL, P<0.01) and Apo B/A1 ratios (-0.2, P<0.01) all decreased in those who went on combination therapy, whereas Apo A1 (9.5 mg/dL, P=0.01) levels increased.
  
  
  CONCLUSIONS
  Treatment with pravastatin or fenofibrate improves the atherogenic lipid profile within the first 12 weeks and is sustained through 48 weeks with combination therapy. Adiponectin levels decrease with lipid-lowering therapy. However, markers of inflammation and platelet activation were not appreciably changed suggesting that the biologic properties of these agents differ in persons with HIV infection.
authors.affiliation: Division of Infectious Diseases, Department of Internal Medicine, University of Cincinnati College of Medicine, PO Box 670405, 231 Albert Sabin Way, Cincinnati, OH 45267-0405, USA. carl.fichtenbaum@uc.edu
authors.forename: Carl J
authors.initials: CJ
authors.lastname: Fichtenbaum
authors.forename: Tzu-Min
authors.initials: TM
authors.lastname: Yeh
authors.forename: Scott R
authors.initials: SR
authors.lastname: Evans
authors.forename: Judith A
authors.initials: JA
authors.lastname: Aberg
mesh_terms: D052242:Adiponectin / Q000097:blood; D000328:Adult; D000368:Aged; D044966:Anti-Retroviral Agents / Q000627:therapeutic use; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D001054:Apolipoproteins A / Q000097:blood; D001055:Apolipoproteins B / Q000097:blood; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000032:analysis; D004334:Drug Administration Schedule; D050171:Dyslipidemias / Q000150:complications / Q000188:drug therapy*; D005260:Female; D011345:Fenofibrate / Q000627:therapeutic use*; D015658:HIV Infections / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D019007:P-Selectin / Q000097:blood; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood; D017035:Pravastatin / Q000627:therapeutic use*; D012367:RNA, Viral / Q000097:blood
chemical_list: D052242:Adiponectin; D044966:Anti-Retroviral Agents; D000924:Anticholesteremic Agents; D001054:Apolipoproteins A; D001055:Apolipoproteins B; D015415:Biomarkers; D019007:P-Selectin; D017395:Plasminogen Activator Inhibitor 1; D012367:RNA, Viral; D002097:C-Reactive Protein; D017035:Pravastatin; D011345:Fenofibrate
references.citation: Int J Cardiol. 2006 Jan 13;106(2):183-90
references.pmid: 16321690
references.citation: JAMA. 2001 Jul 4;286(1):64-70
references.pmid: 11434828
references.citation: N Engl J Med. 1996 Oct 3;335(14):1001-9
references.pmid: 8801446
references.citation: Lancet. 2005 Nov 26;366(9500):1849-61
references.pmid: 16310551
references.citation: Eur J Clin Chem Clin Biochem. 1995 Jun;33(6):337-42
references.pmid: 7578614
references.citation: AIDS Res Hum Retroviruses. 2005 Sep;21(9):757-67
references.pmid: 16218799
references.citation: Atherosclerosis. 2007 Oct;194(2):e43-51
references.pmid: 17112529
references.citation: JAMA. 2004 Sep 15;292(11):1365-7
references.pmid: 15337731
references.citation: Atherosclerosis. 2004 Feb;172(2):273-9
references.pmid: 15019537
references.citation: Blood. 1988 Jan;71(1):220-5
references.pmid: 3257145
references.citation: AIDS. 2006 Apr 24;20(7):1003-10
references.pmid: 16603852
references.citation: J Cardiovasc Pharmacol. 1996 Apr;27(4):563-70
references.pmid: 8847874
references.citation: Circulation. 2002 Mar 12;105(10):1162-9
references.pmid: 11889008
references.citation: JAMA. 2004 Mar 3;291(9):1071-80
references.pmid: 14996776
references.citation: N Engl J Med. 2006 Jul 13;355(2):125-37
references.pmid: 16837676
references.citation: Circulation. 1998 May 12;97(18):1784-90
references.pmid: 9603532
references.citation: N Engl J Med. 1999 Aug 5;341(6):410-8
references.pmid: 10438259
references.citation: N Engl J Med. 2006 Nov 30;355(22):2283-96
references.pmid: 17135583
references.citation: BMJ. 2003 Jun 28;326(7404):1423
references.pmid: 12829554
references.citation: Am Heart J. 2004 Apr;147(4):E18
references.pmid: 15077088
references.citation: Circulation. 2000 Jul 4;102(1):21-7
references.pmid: 10880410
references.citation: Circulation. 2004 Jun 1;109(21 Suppl 1):II34-41
references.pmid: 15173061
references.citation: AIDS. 2003 Nov 21;17(17):2479-86
references.pmid: 14600519
references.citation: N Engl J Med. 2003 Nov 20;349(21):1993-2003
references.pmid: 14627784
references.citation: Arterioscler Thromb Vasc Biol. 2003 Jan 1;23(1):85-9
references.pmid: 12524229
references.citation: N Engl J Med. 2005 Apr 21;352(16):1685-95
references.pmid: 15843671
references.citation: N Engl J Med. 2005 Jan 6;352(1):29-38
references.pmid: 15635110
references.citation: AIDS. 2002 Mar 8;16(4):569-77
references.pmid: 11873000
references.citation: Diabetes Care. 2005 Jun;28(6):1419-24
references.pmid: 15920062
references.citation: N Engl J Med. 1995 Nov 16;333(20):1301-7
references.pmid: 7566020
references.citation: J Am Coll Cardiol. 2005 May 17;45(10):1644-8
references.pmid: 15893181
references.citation: N Engl J Med. 1987 Nov 12;317(20):1237-45
references.pmid: 3313041
references.citation: HIV Clin Trials. 2007 Jan-Feb;8(1):53-60
references.pmid: 17434849
references.citation: J Am Coll Cardiol. 2005 May 17;45(10):1649-53
references.pmid: 15893182